PLoS ONE (Jan 2015)

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

  • Sarah Gooding,
  • I-Jun Lau,
  • Mimi Sheikh,
  • Pamela Roberts,
  • Julia Wong,
  • Emmy Dickens,
  • Ash Bullement,
  • Jamie Elvidge,
  • Dawn Lee,
  • Karthik Ramasamy

DOI
https://doi.org/10.1371/journal.pone.0136207
Journal volume & issue
Vol. 10, no. 9
p. e0136207

Abstract

Read online

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411-£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.